Takeda Pharmaceutical (TAK) Retained Earnings (2017 - 2026)

Takeda Pharmaceutical has reported Retained Earnings for 10 years, with the latest figure at $4.2 billion in Q2 2026.

• On a quarterly basis, Retained Earnings fell 47.65% year-over-year to $4.2 billion in Q2 2026; TTM through Jun 2026 was $4.2 billion, a 47.65% decrease from a year earlier, with the FY2026 full-year figure at $4.5 billion, down 41.73% from the prior year.
• Retained Earnings was $4.2 billion for Q2 2026 at Takeda Pharmaceutical, down from $4.5 billion in the prior quarter.
• The five-year high for Retained Earnings was $12.7 billion in Q1 2022, with the low at $4.2 billion in Q2 2026.
• Average Retained Earnings over 5 years is $9.0 billion, with a median of $9.4 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Retained Earnings fell 3.67% in 2023, then slumped 47.65% in 2026.
• Over 5 years, Retained Earnings stood at $10.7 billion in 2022, then fell by 11.45% to $9.4 billion in 2023, then fell by 10.14% to $8.5 billion in 2024, then dropped by 16.16% to $7.1 billion in 2025, then tumbled by 41.22% to $4.2 billion in 2026.
• The last three Retained Earnings figures came in at $4.2 billion (Q2 2026), $4.5 billion (Q1 2026), and $7.1 billion (Q4 2025), per Business Quant data.